DENTSPLY SIRONA Files 8-K: Corporate Updates

TL;DR

DSNY filed an 8-K on Dec 3rd covering Reg FD, other events, and financials. Stay tuned.

AI Summary

DENTSPLY SIRONA Inc. filed an 8-K on December 3, 2024, reporting on various events including a Regulation FD Disclosure, other events, and financial statements/exhibits. The filing details the company's principal executive offices in Charlotte, North Carolina, and its incorporation in Delaware.

Why It Matters

This 8-K filing provides crucial updates on DENTSPLY SIRONA's corporate activities and financial reporting, which are important for investors to monitor.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediate negative news or significant risk factors.

Key Players & Entities

• DENTSPLY SIRONA Inc. (company) — Registrant
• December 3, 2024 (date) — Date of Report
• Charlotte, North Carolina (location) — Principal Executive Offices
• Delaware (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share XRAY The Nasdaq Stock Market

Filing Documents

• xray-20241203.htm (8-K) — 29KB
• exhibit991interimcfopres.htm (EX-99.1) — 4KB
• exhibit991interimcfopres001.jpg (GRAPHIC) — 228KB
• exhibit991interimcfopres002.jpg (GRAPHIC) — 34KB
• 0000818479-24-000099.txt ( ) — 519KB
• xray-20241203.xsd (EX-101.SCH) — 2KB
• xray-20241203_lab.xml (EX-101.LAB) — 21KB
• xray-20241203_pre.xml (EX-101.PRE) — 13KB
• xray-20241203_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure As previously disclosed, on November 7, 2024, German authorities conducted searches at the Company's sites in Bensheim and Hanau, Germany. By way of background, following the merger of DENTSPLY International Inc. and Sirona Dental Systems, Inc., the combined entity, DENTSPLY SIRONA Inc. (the "Company"), arranged a series of intercompany loans as part of post-merger integration activities for tax years 2016 and 2017. The Company engaged external experts to review and provide guidance on these transactions, to ensure they were structured at arm's length and aligned with applicable legal requirements. The 2016-2017 tax years are under audit, and the Company has been in discussions with the German tax authorities regarding the business purpose of the loans and the deductibility of related interest expenses. The searches are part of a criminal investigation into these post-merger integration transactions. No charges have been filed against the Company or any individuals. The Company intends to fully cooperate and assert its positions, including pursuing appeals, as necessary. The information furnished pursuant to this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01 Other Events

Item 8.01 Other Events On December 3, 2024, the Company announced the appointment of Herman V. Cueto as the Company's interim Chief Financial Officer, who will serve until the Company identifies and appoints a permanent Chief Financial Officer. As interim Chief Financial Officer, Mr. Cueto will support Simon D. Campion, the Company's President and Chief Executive Officer, who will continue to serve as the Company's principal financial officer until the Company identifies and appoints a permanent Chief Financial Officer. Mr. Cueto most recently served as Executive Vice President and Chief Financial Officer at Azenta Life Sciences, Inc. ("Azenta"), a leading provider of life science solutions worldwide. Prior to Azenta, Mr. Cueto was Senior Vice President of Finance at Becton, Dickinson and Company ("BD"), overseeing Segments, Regions, Business Planning and Analysis and Operations. Mr. Cueto joined BD in 2017 through its acquisition of C. R. Bard, Inc. ("Bard"). Mr. Cueto held positions at Bard for fourteen years, and he served as Vice President and Group CFO at the time of the acquisition. A copy of the press release announcing the appointment of Mr. Cueto is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits: 99.1 DENTSPLY SIRONA Inc. press release dated December 3, 2024 as referenced in Item 8.01 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENTSPLY SIRONA Inc. By: /s/ Richard C. Rosenzweig Richard C. Rosenzweig Executive Vice President, Corporate Development, General Counsel and Secretary Date: December 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR